This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Endometrial Cancer, Endometrial Carcinoma or Neoplasms, Endometrial
and you are
over 18
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

Due to the high expression of PD-L1 in endometrial cancers as well as in ovarian cancers which are molecularly similar to uterine serous cancers, using pembrolizumab should be beneficial in this patient population. Since the investigators are able to get a pre-treatment research- related endometrial biopsy as well as the surgical specimen post two cycles of pembrolizumab, the investigators will be able to evaluate the mechanism of action of this drug on the endometrial cancer tumor environment.

Provided treatments

  • Drug: MK-3475
  • Procedure: Surgical resection (standard of care)
  • Drug: Paclitaxel (standard of care)
  • Drug: Carboplatin (standard of care)
  • Radiation: Radiation (standard of care)
  • Procedure: Endometrial biopsy
  • Procedure: Peripheral blood draw

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02630823. The sponsor of the trial is Washington University School of Medicine and it is looking for 10 volunteers for the current phase.
Official trial title:
Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma